» Articles » PMID: 22829203

Personalized Nanomedicine

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2012 Jul 26
PMID 22829203
Citations 65
Authors
Affiliations
Soon will be listed here.
Abstract

Personalized medicine aims to individualize chemotherapeutic interventions on the basis of ex vivo and in vivo information on patient- and disease-specific characteristics. By noninvasively visualizing how well image-guided nanomedicines-that is, submicrometer-sized drug delivery systems containing both drugs and imaging agents within a single formulation, and designed to more specifically deliver drug molecules to pathologic sites-accumulate at the target site, patients likely to respond to nanomedicine-based therapeutic interventions may be preselected. In addition, by longitudinally monitoring how well patients respond to nanomedicine-based therapeutic interventions, drug doses and treatment protocols can be individualized and optimized during follow-up. Furthermore, noninvasive imaging information on the accumulation of nanomedicine formulations in potentially endangered healthy tissues may be used to exclude patients from further treatment. Consequently, combining noninvasive imaging with tumor-targeted drug delivery seems to hold significant potential for personalizing nanomedicine-based chemotherapeutic interventions, to achieve delivery of the right drug to the right location in the right patient at the right time.

Citing Articles

Nanotechnology-driven EGCG: bridging antioxidant and therapeutic roles in metabolic and cancer pathways.

Esmaeili Z, Shavali Gilani P, Khosravani M, Motamedi M, Maleknejad S, Adabi M Nanomedicine (Lond). 2025; 20(6):621-636.

PMID: 39924937 PMC: 11881875. DOI: 10.1080/17435889.2025.2462521.


Hybrid Cell Membrane-Engineered Nanocarrier for Triple-Action Strategy to Address Pseudomonas aeruginosa Infection.

Zhang S, Chen T, Lu W, Lin Y, Zhou M, Cai X Adv Sci (Weinh). 2024; 12(6):e2411261.

PMID: 39721013 PMC: 11809413. DOI: 10.1002/advs.202411261.


Comprehensive insights into glioblastoma multiforme: drug delivery challenges and multimodal treatment strategies.

Dhiman A, Rana D, Benival D, Garkhal K Ther Deliv. 2024; 16(1):87-115.

PMID: 39445563 PMC: 11703381. DOI: 10.1080/20415990.2024.2415281.


Nano-omics: Frontier fields of fusion of nanotechnology.

Wang X, Xu W, Li J, Shi C, Guo Y, Shan J Smart Med. 2024; 2(4):e20230039.

PMID: 39188303 PMC: 11236068. DOI: 10.1002/SMMD.20230039.


Stealth Nanocarriers in Cancer Therapy: a Comprehensive Review of Design, Functionality, and Clinical Applications.

Saadh M, Mustafa M, Kumar A, Alamir H, Kumar A, Khudair S AAPS PharmSciTech. 2024; 25(6):140.

PMID: 38890191 DOI: 10.1208/s12249-024-02843-5.